ライフサイエンスコーパス: NS5A

1 1 (NAP1L1) as an interaction partner of HCV NS5A.

2 tance-associated substitutions in NS3 and/or NS5A.

3 sistance-associated substitutions in NS3 and NS5A.

4 of patients had detectable baseline RASs in NS5A.

5 interferon-sensitivity determining region of NS5A.

6 ion of both serine and threonine residues in NS5A.

7 ption alters the subcellular distribution of NS5A.

8 between the globular and disordered parts of NS5A.

9 with an altered subcellular distribution of NS5A.

10 be partially transcomplemented by wild-type NS5A.

11 ation of a replication-defective mutation in NS5A.

12 nction and found that MOBKL1B interacts with NS5A.

13 n the presence of tyrosine at position 93 of NS5A.

14 nted by cyclosporine resistance mutations in NS5A.

15 omain and on tyrosine phosphorylation within NS5A.

16 eline resistance-associated substitutions in NS5A.

17 HCV proteins, including core, E2, NS4B, and NS5A.

18 potent antiviral drugs that are targeted to NS5A.

19 without altering HCV RNA colocalization with NS5A.

20 eline resistance-associated substitutions in NS5A, 25 (89% [95% CI 72-98]) of 28 patients without cir

21 N2034D, E2238G, V2252A, L2266P, and I2340T [NS5A]; A2500S and V2841A [NS5B]), displayed fitness comp

22 ors (39%) than mice that did not express HCV NS5A after the HCFD (6%); only 9% of Tlr4-/- NS5A Tg mic

23 Furthermore, expression of NS5A alone from an additional cistron within a replicon

24 the hepatitis C virus nonstructural protein NS5A, anchored at the cytoplasmic leaflet of the endopla

25 surrounding cytoplasmic lipid droplets with NS5A and core protein.

26 cted with HCV encoded non-structural protein NS5A and could strongly induce its degradation dependent

27 ar target of the viral nonstructural protein NS5A and demonstrated its role in antiviral signaling.

28 the 7 clinically relevant inhibitors of HCV NS5A and identified variants associated with resistance

29 nificantly enhanced by mutations in NS4B and NS5A and in cell clones cured of replicon RNA.

30 ther detailed structure/function analysis of NS5A and M3R performed by the ISM method extended with o

31 Our results help to define the function of NS5A and may contribute to an understanding of the mode

32 tures and study the effects of inhibitors of NS5A and NS5B and resistance to sofosbuvir-the only nucl

33 9860 genotype and variants in the NS3, NS4A, NS5A and NS5B HCV proteins.

34 ubsequent selection by DAA treatment of both NS5A and NS5B S282 RASs.

35 ange that stabilized the interaction between NS5A and TBC1D20, which is required for HCV replication.

36 we demonstrate that the interaction between NS5A and the c-Src SH2 domain strictly depends on an int

37 ldown assays revealed an interaction between NS5A and the Src homology 2 (SH2) domain of c-Src; howev

38 itis C virus (HCV) nonstructural protein 5A (NS5A) and effects on the viral life cycle.

39 itis C virus (HCV) nonstructural protein 5A (NS5A) and its interaction with the human chaperone cyclo

40 We compared RASs in NS3, NS5A, and NS5B among patients failed by DAA therapy.

41 uencing of the nonstructural protein (NS) 3, NS5A, and NS5B genes was performed in all subtype 4r pat

42 nd/or deep sequence analyses of the HCV NS3, NS5A, and NS5B genes were performed on blood samples col

43 Deep sequencing of the NS3, NS5A, and NS5B regions were performed at baseline, at in

44 We compared NS3, NS5A, and NS5B sequences from 626 patients in Europe wit

45 RAVs in NS3, NS5A, and NS5B were detected by population-based sequenc

46 or sofosbuvir and high concentrations of HCV NS5A antivirals but not by NS3 protease inhibitors.

47 oteins NS3/4A protease, NS5B polymerase, and NS5A are clinically validated targets for direct-acting

48 the N terminus of CIDEB and the domain I of NS5A are involved in this interaction.

49 HCV genotype 1a infection, polymorphisms in NS5A at baseline (before treatment) can affect the effic

50 orylation of the viral nonstructural protein NS5A at serine residues is important for the efficient a

51 ts who had failed to achieve SVR on previous NS5A-based therapy with daclatasvir (DCV) plus pegylated

52 ified the mitochondrial protein LRPPRC as an NS5A binding factor.

53 The N-terminal amphipathic helix of NS5A bound specifically to PI(4,5)P2, inducing a conform

54 ylation of Tyr-93 located within domain 1 of NS5A, but not of any other tyrosine residue, is crucial

55 the effects of PI(4,5)P2 on the function of NS5A by expressing wild-type or mutant forms of Bart79I

56 each other: one inhibitor binds to resistant NS5A, causing a conformational change that is transmitte

57 pre-existing RAS T/Y93H acquired additional NS5A changes during escape experiments, resulting in HCV

58 Ser-235 phosphorylated NS5A co-localized with double-stranded RNA, consistent w

59 NS5A comprises an N-terminal folded domain, followed by

60 nclusion: Overall, our results indicate that NS5A contributes to the inhibition of innate immune path

61 y a short structural motif in the disordered NS5A-D2 and report its NMR structure.

62 is strongly impaired in the binding of both NS5A-D2 and RNA.

63 Thus, our work highlights NS5A-D2 as an allosteric regulator of the HCV polymerase

64 NS5A-D2 comprises a short structural motif (PW-turn) emb

65 found that the fraction of conformers in the NS5A-D2 ensemble that adopt the structured motif is allo

66 NS5A-D2 induces conformational and functional perturbati

67 The addition of NS5A-D2 leads to spectral changes indicative of binding

68 f NS5B in solution and its relationship with NS5A-D2 remains incomplete.

69 rdered domain 2 of nonstructural protein 5A (NS5A-D2) of hepatitis C virus (HCV).

70 e intrinsically disordered domain 2 of NS5A (NS5A-D2), another essential multifunctional HCV protein

71 -tune the dynamic ensemble of the disordered NS5A-D2, thereby regulating viral RNA replication effici

72 ns isomerase activity on residue Pro(314) of NS5A-D2.

73 sed of only the C-terminal residues 191-447 (NS5A-D2D3) allowed us to conclude that there is no signi

74 NS5A-D2D3, despite its overall high flexibility, shows a

75 ons from a culture-efficient JFH1-based core-NS5A (DBN) recombinant, was transfected into Huh7.5 cell

76 ensive domain mapping analyses revealed that NS5A degradation was mediated by the highly conserved SP

77 ion will allow structure-based design of new NS5A directed compounds with higher barriers to HCV resi

78 F/VEL/VOX) achieved an SVR12 rate of >95% in NS5A-experienced participants.

79 as well as HCV chimeric replicons containing NS5A fragments from genotypes 2-6.

80 We expressed HCV-NS5A from a transgene (NS5A Tg) in Tlr4-/- (C57Bl6/10ScN

81 However, only NS5A from genotype 2 HCV, and not that from genotype 1,

82 could be rescued benefitted from expressing NS5A from the same RNA being packaged.

83 ge interactions in nonstructural protein 5A (NS5A) from hepatitis C virus (HCV), a typical viral IDP

84 actors involved in HCV nonstructural protein NS5A function and found that MOBKL1B interacts with NS5A

85 We showed further that the NS5A-GBP1 interaction inhibited GTPase activity, which w

86 trees based on HCV NS5B (genotype 1a/4d) or NS5A (genotype 3a) Sanger sequencing.

87 NS5A has multiple functions during the virus life cycle,

88 Baseline RASs in NS5A have minimal effects on patient responses to ledipa

89 GSK2818713 (13), a nonstructural protein 5A (NS5A) HCV inhibitor characterized by a significantly imp

90 switch to regulate the various functions of NS5A; however, the mechanistic details of the role of th

91 t-derived NS5A sequences by using genotype 4 NS5A hybrid genotype 2a replicons.

92 cell environment by targeting NAP1L1 through NS5A.IMPORTANCE Viruses have evolved to replicate and to

93 Mouse hepatocytes that express HCV-NS5A in liver up-regulate the expression of Toll-like re

94 ion therapy and new insight into the role of NS5A in the HCV replication cycle.

95 for phosphorylation at serine 225 (S225) of NS5A in the regulation of JFH-1 (genotype 2a) genome rep

96 HCV dsRNAs (Core, E1-P7, NS-3'NTR and NS5A) induced interferon-lambda1 (IFN-lambda1) expressio

97 asvir targets a mutual, specific function of NS5A inhibiting both processes.

98 ong 13 patients exposed to sofosbuvir and an NS5A inhibitor (daclatasvir, ledipasvir, or velpatasvir)

99 The addition of another potent agent, the NS5A inhibitor ABT-267, may improve efficacy, especially

100 Here we show that although DCV and an NS5A inhibitor analogue (Syn-395) are inactive against c

101 ation of an NS3/4A protease inhibitor and an NS5A inhibitor approved for the treatment of chronic HCV

102 Daclatasvir is an NS5A inhibitor approved for treatment of infection due t

103 f acid 1, a penultimate precursor to the HCV NS5A inhibitor BMS-986097, along with the final API step

104 Daclatasvir and ledipasvir belong to the NS5A inhibitor class, which directly target the NS5A pro

105 eatment response with IFNL4 genotype in some NS5A inhibitor containing IFN-free regimens.

106 notype coverage relative to first-generation NS5A inhibitor daclatasvir (DCV), is detailed herein.

107 S3/4A protease inhibitor grazoprevir and the NS5A inhibitor elbasvir together with ribavirin in treat

108 r findings support the concept of retreating NS5A inhibitor failures with SOF combined with SIM.

109 ated with a combination of sofosbuvir and an NS5A inhibitor for 8 weeks.

110 ON program, the single-tablet regimen of the NS5A inhibitor ledipasvir and NS5B nucleotide polymerase

111 ed-dose combination of the hepatitis C virus NS5A inhibitor ledipasvir and the NS5B nucleotide polyme

112 y and safety of combination therapy with the NS5A inhibitor ledipasvir and the NS5B polymerase inhibi

113 We assessed the efficacy and safety of the NS5A inhibitor ledipasvir and the nucleotide polymerase

114 -label study, we assessed treatment with the NS5A inhibitor ledipasvir, the nucleotide polymerase inh

115 f compound 57, a highly potent and selective NS5A inhibitor of HCV (EC50 = 4.6 nM), with greater ther

116 to discover solubilizing prodrugs of the HCV NS5A inhibitor pibrentasvir (PIB) identified phosphometh

117 S3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults who h

118 of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhib

119 NS5B polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir for HCV in patients coinfecte

120 tide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir in a once-daily, fixed-dose c

121 tide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir once daily for 12 weeks, sofo

122 tide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sus

123 leotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhi

124 leotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhi

125 leotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor v

126 erase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir.

127 previously received a DAA regimen but not an NS5A inhibitor were randomly assigned in a 1:1 ratio to

128 previously received a regimen containing an NS5A inhibitor were randomly assigned in a 1:1 ratio to

129 BACKGROUND & AIMS: Elbasvir (an NS5A inhibitor) and grazoprevir (an NS3/4A protease inhi

130 Elbasvir (an NS5A inhibitor) and grazoprevir (an NS3/4A protease inhi

131 of two direct-acting antivirals, ombitasvir (NS5A inhibitor) and paritaprevir (NS3/4A protease inhibi

132 93 (NS3/4A protease inhibitor) plus ABT-530 (NS5A inhibitor) has shown high rates of sustained virolo

133 e-daily dosage of daclatasvir (pan-genotypic NS5A inhibitor) in combination with sofosbuvir at 400 mg

134 tor) and two doses of elbasvir (MK-8742; HCV NS5A inhibitor) in patients with HCV mono-infection and

135 se inhibitor) combined with elbasvir (an HCV NS5A inhibitor) with or without ribavirin in patients wi

136 d previous treatment with sofosbuvir plus an NS5A inhibitor, 16 weeks treatment with G/P produced sus

137 al interferon-free regimen of ombitasvir, an NS5A inhibitor, and paritaprevir (ABT-450), an NS3/4A pr

138 direct-acting antiviral drugs ombitasvir, an NS5A inhibitor, and paritaprevir, an NS3/4A protease inh

139 All patients received ledipasvir, an NS5A inhibitor, and sofosbuvir, a nucleotide polymerase

140 on of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has sh

141 (NS3/4A inhibitor; 100 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ru

142 (HCV genotypes 1-6) while the indication for NS5A inhibitor- naive patients was limited to HCV genoty

143 nts who had previously relapsed following an NS5A inhibitor-containing all-oral regimen were retreate

144 ribavirin, in participants who had failed an NS5A inhibitor-containing regimen.

145 with HCV infection who had previously failed NS5A inhibitor-containing therapy.

146 t as to why a broad indication was given for NS5A inhibitor-experienced patients (HCV genotypes 1-6)

147 rapy with an NS3 protease inhibitor and dual NS5A inhibitor-NS5B nucleotide analogue.

148 eral blood in a few weeks to months, whereas NS5A inhibitor-resistant viruses persist for years.

149 HCV regimen containing sofosbuvir without an NS5A inhibitor.

150 HCV regimen containing sofosbuvir without an NS5A inhibitor.

151 ergy when combined with interferon or an HCV NS5A inhibitor.

152 r of patients failing regimens containing an NS5A inhibitor.

153 h treatment failure after sofosbuvir plus an NS5A inhibitor.

154 th treatment failure after sofosbuvir and an NS5A inhibitor.

155 d previous treatment with sofosbuvir plus an NS5A inhibitor.

156 itor; 100 mg/day) plus ruzasvir (MK-8408; an NS5A inhibitor; 60 mg/day) plus uprifosbuvir (MK-3682; a

157 /4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (d

158 ing daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes,

159 gimen containing a nonstructural protein 5A (NS5A) inhibitor; and * genotype 1a or 3 infection and ha

160 of salvage SOF/VEL/VOX for HCV infection in NS5A-inhibitor experienced participants with cirrhosis a

161 L/VOX for the treatment of difficult-to-cure NS5A-inhibitor experienced patients, including those wit

162 with daclatasvir (nonstructural protein 5A [NS5A] inhibitor), asunaprevir (NS3 protease inhibitor),

163 ared the efficacy of all clinically relevant NS5A inhibitors against HCV genotype 1-7 prototype isola

164 The presence of viral variants resistant to NS5A inhibitors at baseline is associated with lower rat

165 NS5A inhibitors did not affect NS5A stability or dimeriz

166 NS5A inhibitors had varying levels of efficacy against o

167 For the remaining NS5A inhibitors tested, RAS at amino acids 28 and 93 led

168 Pan-genotype NS5A inhibitors underpin hugely successful hepatitis C v

169 Cells incubated with NS5A inhibitors were rapidly depleted of intracellular i

170 ion of a novel class of potent pan-genotypic NS5A inhibitors with good pharmacokinetic profile suitab

171 selecting for resistance in the NS5A region (NS5A inhibitors), promises to revolutionize HCV treatmen

172 in the NS5A region conferring resistance to NS5A inhibitors, such as ledipasvir.

173 l chemical class of potent and selective HCV NS5A inhibitors.

174 who have failed on nonstructural protein 5A (NS5A) inhibitors should be retreated with sofosbuvir (SO

175 pectedly, an HCV variant lacking the MOBKL1B-NS5A interaction could not replicate after cells were tr

176 ree proteomics approach to identify cellular NS5A interaction partners.

177 ably promotes HCV replication via increasing NS5A interaction with the 33-kDa vesicle-associated memb

178 replication complex formation via increasing NS5A interaction with the human homologue of the 33-kDa

179 NS5A is a phosphoprotein, and it has been proposed that

180 Finally, we demonstrated that NS5A is able to interfere with MAVS activity in a LRPPRC

181 NS5A is known to be phosphorylated by cellular protein k

182 NS5A is required for HCV RNA replication and is involved

183 rugs to counteract the worldwide HCV burden, NS5A is still an enigmatic multifunctional protein poorl

184 The non-structural protein 5A (NS5A) is a hepatitis C virus (HCV) protein indispensable

185 HCV non-structural protein 5A (NS5A) is a multifunctional protein required for several

186 itis C virus (HCV) nonstructural protein 5A (NS5A) is a phosphoprotein that plays key, yet poorly def

187 The viral nonstructural 5A protein (NS5A) is the target for new antiviral drugs.

188 d the level and translation of Netrin-1 in a NS5A-La-related protein 1 (LARP1)-dependent fashion.

189 n of CypA rescues PKR from antagonism by HCV NS5A, leading to activation of an interferon regulatory

190 ion sites (serines 222, 235, and 238) in the NS5A low complexity sequence I region.

191 ariants encoding amino acid polymorphisms in NS5A (M28, Q30, L31, or Y93) reduced treatment efficacy;

192 7) in a large cluster, in which 96% harbored NS5A M28V RAS.

193 for compensated genotype 1b HCV if baseline NS5A mutations are absent.

194 tracellular colocalization between core, E2, NS5A, NS4B proteins, and viral RNAs was quantitatively a

195 eplication complex (RC) characterized by HCV NS5A, NS4B, or double-stranded RNA (dsRNA) foci.

196 ith the intrinsically disordered domain 2 of NS5A (NS5A-D2), another essential multifunctional HCV pr

197 ) in HCV genes (nonstructural protein [NS]3, NS5A, NS5B) targeted by DAAs.

198 HCV antivirals targeting NS5A, NS5B, and microRNA-122 efficiently inhibited RHV r

199 effects of baseline hepatitis C virus (HCV) NS5A, NS5B, and NS3 resistance-associated substitutions

200 teraction and mapped it to the C terminus of NS5A of both genotype 1 and 2.

201 as no significant effect of baseline RASs in NS5A on sustained viral response 12 weeks after the end

202 ased on experimental results suggesting that NS5A- or protease-inhibitors can generate non-infectious

203 ay be important for some of the functions of NS5A over the course of the HCV life cycle.

204 plication defect that mapped to domain II of NS5A (P315A, L321A).

205 Mechanisms regulating NS5A phosphorylation and its exact function in the HCV l

206 g to the host protein Bin1, as well as after NS5A phosphorylation by CK2.

207 ty sequence I region of NS5A responsible for NS5A phosphorylation; however, the functions of specific

208 dings indicate that phosphorylated Tyr-93 in NS5A plays an important role during viral replication by

209 itis C virus (HCV) nonstructural protein 5A (NS5A) plays a key role in viral replication and virion a

210 Most baseline sequences had >/=1 NS5A polymorphism at residues associated with daclatasvi

211 2 relapses, and was associated with baseline NS5A polymorphisms and emergent NS3 or NS5A variants or

212 HCV database, and susceptibility analyses of NS5A polymorphisms and patient-derived NS5A sequences by

213 ation for HCV genotype 4 subtype prevalence, NS5A polymorphisms at residues associated with daclatasv

214 s with HCV genotype 4a or 4d infections with NS5A polymorphisms, all 26 who received the elbasvir and

215 ere 70% and 98% for patients with or without NS5A polymorphisms, respectively (P < .0001).

216 patients with HCV genotype 1a infection with NS5A polymorphisms.

217 abile Zn-site in the hepatitis C virus (HCV) NS5A protein and showed that the antialcoholism drug, di

218 S: Inhibitors of the hepatitis C virus (HCV) NS5A protein are a key component of effective treatment

219 raction of a pair of compounds suggests that NS5A protein molecules communicate with each other: one

220 ssays revealed that GBP1 interacted with the NS5A protein of CSFV, and this interaction was mapped in

221 This analysis revealed that NS5A protein represents the most probable interactor of

222 nst CSFV replication, and the binding of the NS5A protein to GBP1 antagonizes the GTPase activity and

223 mbination with elbasvir, an inhibitor of HCV NS5A protein) showed that positions 56, 156, and 168 in

224 Furthermore, CIDEB interacts with the HCV NS5A protein, and the N terminus of CIDEB and the domain

225 on a specific amino acid residue in the HCV NS5A protein.

226 the intrinsically disordered domain 2 of HCV NS5A protein.

227 udy specific binding of PI(4,5)P2 by the HCV NS5A protein.

228 A inhibitor class, which directly target the NS5A protein.

229 he hepatitis C virus (HCV) nonstructural 5A (NS5A) protein is highly phosphorylated and involved in b

230 The HCV nonstructural 5A (NS5A) protein, in addition to its role in viral replicat

231 ith HCV recombinants expressing genotype 1-7 NS5A proteins with or without RAS.

232 egulated by hepatitis C virus (HCV) core and NS5A proteins, and this negative regulation is apparent

233 eletion or transgenic expression of HCV core/NS5A proteins, promotes the activation of Wnt/beta-caten

234 .6%) of 13 patients with detectable baseline NS5A RASs and in 98 (100%) of 98 without.

235 These same baseline NS5A RASs reduced the percentage of treatment-experience

236 The NS5A RAV Y93H is significantly associated with the prese

237 In contrast, the NS5A RAV Y93H was detected frequently in HCV genotype 1b

238 In addition, IFNL4 SNPs and NS5A RAVs were analyzed including deep sequencing (n = 1

239 Human replication protein A (RPA) and HCV NS5A recruit NS5BDelta21 to the template.

240 luding these selecting for resistance in the NS5A region (NS5A inhibitors), promises to revolutionize

241 aled a resistance associated mutation in the NS5A region conferring resistance to NS5A inhibitors, su

242 the mechanism of this inhibitory activity of NS5A remains partly characterized.

243 3 provided clinical proof-of-concept for the NS5A replication complex inhibitor class, and regulatory

244 asunaprevir (64), marketed as Sunvepra, the NS5A replication complex inhibitor daclatasvir (117), ma

245 el trial of the combination of ombitasvir (a NS5A replication complex inhibitor), paritaprevir, and r

246 NS5A replication complex inhibitors, exemplified by dacl

247 ional change that is transmitted to adjacent NS5As, resensitizing resistant NS5A so that the second i

248 logue (Syn-395) are inactive against certain NS5A resistance variants, combinations of the pair enhan

249 e 4r patients harbored two to three dominant NS5A resistance-associated substitutions (RASs), includi

250 NS5A resistance-associated substitutions detected at bas

251 12 weeks of LDV/SOF, even for patients with NS5A resistance-associated variants.

252 , a non-CC IL-28B genotype, and pretreatment NS5A resistance-associated variants.

253 Of the 76 patients with baseline NS5A resistant variants, 75 (99%) achieved SVR12.

254 Prior to retreatment, 29 patients (85%) had NS5A-resistant variants.

255 s in the low complexity sequence I region of NS5A responsible for NS5A phosphorylation; however, the

256 ole during viral replication by facilitating NS5A's interaction with the SH2 domain of c-Src.

257 We showed that HCV NS5A(S25-C447) and cellular replication protein A (RPA)

258 Both RPA and NS5A(S25-C447), but not NS5A(S25-K215), enabled the NS5B

259 Both RPA and NS5A(S25-C447), but not NS5A(S25-K215), enabled the NS5BDelta21-NS3 helicase com

260 apitulated the perinuclear redistribution of NS5A seen in the S225A mutant.

261 es of NS5A polymorphisms and patient-derived NS5A sequences by using genotype 4 NS5A hybrid genotype

262 erformed phylogenetic analysis of genotype 4 NS5A sequences from 186 clinical trial patients and 43 s

263 ective concentrations for 10 patient-derived NS5A sequences representing diverse phylogenetic cluster

264 NS5A sequesters NAP1L1 in the cytoplasm, blocking its nu

265 We concluded that NS5A Ser-235 phosphorylated by CKIalpha probably promote

266 d to adjacent NS5As, resensitizing resistant NS5A so that the second inhibitor can act to restore inh

267 NS5A inhibitors did not affect NS5A stability or dimerization.

268 tion of embryonic gene clusters, whereas the NS5A TCR activation induced extended proliferative and m

269 A higher proportion of NS5A Tg mice developed liver tumors (39%) than mice that

270 NS5A after the HCFD (6%); only 9% of Tlr4-/- NS5A Tg mice fed HCFD developed liver tumors.

271 Livers from NS5A Tg mice fed the HCFD had increased levels of TLR4,

272 n alcohol Western diet-fed hepatitis C virus NS5A Tg mice with hepatocyte-specific TBC1D15 deficiency

273 In TICs from NS5A Tg mice, NANOG and pSTAT3 directly interact to acti

274 We expressed HCV-NS5A from a transgene (NS5A Tg) in Tlr4-/- (C57Bl6/10ScN), and wild-type contro

275 RASs in NS5A that increased the half-maximal effective concentra

276 cise molecular function has been ascribed to NS5A that is composed of a highly structured domain 1 (D

277 eins and show that they interacted only with NS5A that was phosphorylated on a specific residue.

278 of the HCV replication complex consisting of NS5A, the RNA-dependent RNA polymerase NS5B, and c-Src.

279 We and others have identified serine 225 in NS5A to be a phosphorylation site, but the function of t

280 modification is required for the binding of NS5A to other cellular proteins.

281 PI(4,5)P2 binds to HCV NS5A to promote replication of the viral RNA genome in h

282 ficient virus replication and the ability of NS5A to spread throughout the cytoplasm of the cell.

283 HCFD and HCV-NS5A together stimulated TLR4-NANOG and the leptin recep

284 Every NS3 and NS5A variant detected at baseline reappeared at the time

285 activity against genotype 1a (gt1a) and gt1b NS5A variants as well as HCV chimeric replicons containi

286 eline NS5A polymorphisms and emergent NS3 or NS5A variants or both.

287 ding to a panel of phosphorylation-deficient NS5A variants revealed that phosphorylation of Tyr-93 lo

288 atidylinositol 4-phosphate), the mutation in NS5A was restricted to a perinuclear region.

289 Y93H in NS5A was the RAS most frequently associated with failure

290 RAS hotspots in NS5A were found at amino acids 28, 30, 31, and 93.

291 RASs in NS5A were heterogeneous among patients with HCV genotype

292 sistance-associated substitutions in NS3 and NS5A were observed in 9 and 10 patients with treatment f

293 and a perinuclear restricted distribution of NS5A, whereas the corresponding phosphomimetic mutation

294 ting antiviral agent and potent inhibitor of NS5A, which is involved in replication of the hepatitis

295 ting antiviral agent and potent inhibitor of NS5A, which is involved in replication of the hepatitis

296 infection is the viral nonstructural protein NS5A, which, in addition to its role in replication and

297 hosphorylation regulates the interactions of NS5A with a defined subset of cellular proteins.

298 S225A mutation disrupted the interactions of NS5A with a number of cellular proteins, in particular t

299 ar magnetic resonance spectra of full-length NS5A with those of a protein construct composed of only

300 nfected with a daclatasvir-resistant mutant (NS5A-Y93H), indicating that daclatasvir targets a mutual